- Home
- Software Solutions
- Resources
- Corporate
Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis
Sponsors:
| Phases:
| |
| Indications | Acronym: ECLA | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 20 | |
Additional information about NCT01473797.